Literature DB >> 11128362

Association between C-reactive protein and features of the metabolic syndrome: a population-based study.

M Fröhlich1, A Imhof, G Berg, W L Hutchinson, M B Pepys, H Boeing, R Muche, H Brenner, W Koenig.   

Abstract

OBJECTIVE: To assess the association of circulating levels of C-reactive protein, a sensitive systemic marker of inflammation, with different components of the metabolic syndrome. RESEARCH DESIGN AND METHODS: Total cholesterol (TC), HDL cholesterol, triglycerides, uric acid, BMI , and prevalence of diabetes and hypertension were assessed in 747 men and 956 women aged 18-89 years who were participating in the population-based National Health and Nutrition Survey, which was carried out in former West Germany in 1987-1988.
RESULTS: There was a statistically significant positive crude correlation between C-reactive protein and TC (R = 0.19), TG (R = 0.29), BMI (R = 0.32), glucose (R = 0.11), and uric acid (R = 0.14) (all P < 0.0001). A negative correlation was found between C-reactive protein and HDL cholesterol (R = 0.13, P < 0.0001). The age-adjusted geometric means of C-reactive protein concentrations in subjects grouped according to the presence of 0-1, 2-3, and > or =4 features of the metabolic syndrome were 1.11, 1.27, and 2.16 mg/l, respectively, with a statistically highly significant trend (P < 0.0001).
CONCLUSIONS: The data suggest that a variety of features of the metabolic syndrome are associated with a systemic inflammatory response.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11128362     DOI: 10.2337/diacare.23.12.1835

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  126 in total

Review 1.  Genetic determinants of diabetes and atherosclerosis.

Authors:  Braxton D Mitchell; Ikhide G Imumorin
Journal:  Curr Atheroscler Rep       Date:  2002-05       Impact factor: 5.113

2.  Non-organ-specific autoantibodies in nonalcoholic fatty liver disease: prevalence and correlates.

Authors:  Paola Loria; Amedeo Lonardo; Francesca Leonardi; Cristina Fontana; Lucia Carulli; Anna Maria Verrone; Andrea Borsatti; Marco Bertolotti; Fabio Cassani; Alberto Bagni; Paolo Muratori; Dorval Ganazzi; Francesco B Bianchi; Nicola Carulli
Journal:  Dig Dis Sci       Date:  2003-11       Impact factor: 3.199

Review 3.  C-reactive protein: a critical update.

Authors:  Mark B Pepys; Gideon M Hirschfield
Journal:  J Clin Invest       Date:  2003-06       Impact factor: 14.808

Review 4.  The immune system in the aging human.

Authors:  Paulina Dominika Rymkiewicz; Yi Xiong Heng; Anusha Vasudev; Anis Larbi
Journal:  Immunol Res       Date:  2012-09       Impact factor: 2.829

Review 5.  Microalbuminuria and C-reactive protein: similar messengers of cardiovascular risk?

Authors:  Stephan J L Bakker; Ron T Gansevoort; Erik M Stuveling; Rijk O B Gans; Dick de Zeeuw
Journal:  Curr Hypertens Rep       Date:  2005-10       Impact factor: 5.369

Review 6.  The role of inflammation as a pathogenic factor in the development of renal disease in diabetes.

Authors:  Carmen Mora; Juan F Navarro
Journal:  Curr Diab Rep       Date:  2005-12       Impact factor: 4.810

7.  Cardiac risk factors in patients with diabetes mellitus and major depression.

Authors:  Wayne J Katon; Elizabeth H B Lin; Joan Russo; Michael Von Korff; Paul Ciechanowski; Greg Simon; Evette Ludman; Terry Bush; Bessie Young
Journal:  J Gen Intern Med       Date:  2004-12       Impact factor: 5.128

Review 8.  Drugs for cardiovascular risk reduction in the diabetic patient.

Authors:  D S Bell
Journal:  Curr Diab Rep       Date:  2001-10       Impact factor: 4.810

Review 9.  Role of inflammatory pathways in the development and cardiovascular complications of type 2 diabetes.

Authors:  Milagros G Huerta; Jerry L Nadler
Journal:  Curr Diab Rep       Date:  2002-10       Impact factor: 4.810

10.  Chronic etanercept treatment prevents the development of hypertension in fructose-fed rats.

Authors:  Linda T Tran; Kathleen M MacLeod; John H McNeill
Journal:  Mol Cell Biochem       Date:  2009-05-07       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.